anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Carboplatin/paclitaxel regimen (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\], and paclitaxel 200 milligram per square meter \[mg/m\^2\]) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal. Subjects were enrolled from North America/European Union (EU) and Japan regions.
Carcinogenesis was evaluated in an 18-month study in mice and a 24-month study in rats. In rats, triptorelin doses of 120, 600, and 3000 mcg/kg given every 28 days (approximately 0.2, 0.8, and 4 times the estimated human monthly dose based on body surface area) resulted in increased mortality with a drug treatment period of 13 to 19 months. The incidences of benign and malignant pituitary tumors and histosarcomas were increased in a dose-related manner. There were no treatment-related tumors in mice at exposure up to 4-fold higher than the estimated human monthly dose based on body surface area.

Mutagenicity studies performed with triptorelin using bacterial and mammalian systems ( in vitroAmes test and chromosomal aberration test in CHO cells and an in vivomouse micronucleus test) provided no evidence of mutagenic potential. 

After 60 days of subcutaneous treatment followed by a minimum of four estrus cycles prior to mating, triptorelin at doses of 2, 20, and 200 mcg/kg (approximately 0.07, 0.7, and 7 times the estimated human daily dose based on body surface area) or two monthly injections as slow release microspheres (~20 mcg/kg/day) had no effect on the fertility or general reproductive function of female rats.

No studies were conducted to assess the effect of triptorelin on male fertility.
Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours. No accumulation of active drug or its metabolites was observed following multiple dose administration. When administered with food, there is a decrease in the rate of absorption, with a fasting TMAX of 1.53 hours and a TMAX of 2.86 hours after a meal; the peak concentration is reduced by 17.3%. Single oral doses across the clinical dose range are dose proportional.

Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins. This suggests that cevimeline is extensively bound to tissues; however, the specific binding sites are unknown.

Metabolism: Isozymes CYP2D6 and CYP3A3/4 are responsible for the metabolism of cevimeline. After 24 hours, 86.7% of the dose was recovered (16.0% unchanged, 44.5% as cis and trans-sulfoxide, 22.3% of the dose as glucuronic acid conjugate and 4% of the dose as N-oxide of cevimeline). Approximately 8% of the trans-sulfoxide metabolite is then converted into the corresponding glucuronic acid conjugate and eliminated. Cevimeline did not inhibit cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4.

Excretion: The mean half-life of cevimeline is 5+/-1 hours. After 24 hours, 84% of a 30 mg dose of cevimeline was excreted in urine. After seven days, 97% of the dose was recovered in the urine and 0.5% was recovered in the feces.

Special Populations: The effects of renal impairment, hepatic impairment, or ethnicity on the pharmacokinetics of cevimeline have not been investigated.
Temporomandibular disorder (TMD) and irritable bowel syndrome (IBS) are 2 chronic overlapping pain conditions (COPCs) that present with significant comorbidity. Both conditions are more prevalent in women and are exacerbated by stress. While peripheral mechanisms might contribute to pain hypersensitivity for each individual condition, mechanisms underlying the comorbidity are poorly understood, complicating pain management when multiple conditions are involved. In this study, longitudinal behavioral and functional MRI-based brain changes have been identified in an animal model of TMD-like pain (masseter muscle inflammation followed by stress) that induces de novo IBS-like comorbid visceral pain hypersensitivity in rats. In particular, data indicate that increased activity in the insula and regions of the reward and limbic systems are associated with more pronounced and longer-lasting visceral pain behaviors in female rats, while the faster pain resolution in male rats may be due to increased activity in descending pain inhibitory pathways. These findings suggest the critical role of brain mechanisms in chronic pain conditions and that sex may be a risk factor of developing COPCs.
RUCONEST is a recombinant analogue of human complement component 1 esterase inhibitor for intravenous injection. RUCONEST is purified from the milk of transgenic rabbits, and supplied as a sterile, preservative-free, white/off-white lyophilized powder for reconstitution for injection. One U of rhC1INH activity is defined as the equivalent of C1 esterase inhibiting activity present in 1 mL of pooled normal plasma.

RUCONEST is a soluble, single-chain glycoprotein containing 478 amino acids, with a molecular mass of 68 kDa, of which approximately 22% comprises oligosaccharide structures. The primary and secondary structures of the molecule and target protease selectivity are consistent with those of plasma-derived C1 esterase inhibitor.

Each vial of RUCONEST contains 2100 U of rhC1INH, 937 mg of sucrose, 83.3 mg of sodium citrate dihydrate and 1.0 mg of citric acid monohydrate. After reconstitution with 14 mL of sterile Water for Injection, each vial of RUCONEST contains 150 U of rhC1INH per 1 mL in a 20 mM sodium citrate buffer with a pH of 6.8. RUCONEST does not contain preservatives and each vial is for single use only.

RUCONEST is purified from the milk of transgenic rabbits. The rabbits are maintained in a closed colony that is controlled and routinely monitored for specific pathogens. The skimmed milk is screened for adventitious contaminants prior to further manufacture. The manufacturing process has been validated to demonstrate adequate capacity for removal and/or inactivation of viruses ( Table 4). RUCONEST contains less than 0.002% of host-related impurities.
PURPOSE: A pharmaceutical composition for preventing or treating enterohemorrhagic E. colibacillosis is provided to show excellent antibacterial activity against enterohemorrhagic O157:H7 using an Agrimonia pilosa extract. CONSTITUTION: A pharmaceutical composition for preventing or treating enterohemorrhagic E. colibacillosis contains an Agrimonia pilosa extract. The extract is prepared from Agrimonia pilosa extract using water, C1-C4, or a mixture thereof. The C1-C4 alcohol is methanol or ethanol. The extract has an antibacterial activity against enterohemorrhagic E.coli O157:H7. [Reference numerals] (AA) Distilled water; (BB) Amphicilin; (CC) Ethanol extract of Agrimonia pilosa
The Investigators will determine whether a questionnaire to identify neuropathic pain in adults is also useful in children. This will help paediatricians and other doctors to recognise neuropathic pain and start appropriate treatment or know when to refer children to a chronic pain clinic.The Investigators will also measure the effects of neuropathic pain on mood, sleep, and quality of life (using questionnaires); identify changes in the sensitivity of the skin to touch and other sensations (using specialised sensory tests); and determine the feasibility of brain imaging for assessing changes in the brain (using magnetic resonance imaging or MRI), in children with neuropathic pain. This information will allow the investigators to measure how effective different types of treatment are, and help ensure children get the most appropriate treatment or interventions to reduce pain and effects on quality of life.

This pilot study of 10-18 year olds diagnosed with neuropathic pain will involve completion of questionnaires by the child and parent, and sensory testing in the child, after their clinic appointment. For some families, there will be an additional visit for MRI. Children will be recruited from the Chronic Pain Outpatients service at Great Ormond Street Hospital NHS Trust. This research is funded by Great Ormond Street Hospital Children's Charity.
A topical skin healing salve and method of making the same for treating and healing a wide variety of injuries, ailments and other skin conditions. The salve of the present invention comprises beeswax, white petroleum jelly or said castor bean jelly, unprocessed honeycomb or honey, yellow dock root, yellow dock leaves, marigold and/or calendula leaves, plantain weed and chickweed. The method of the present invention melts the beeswax, petroleum or castor bean jelly and honeycomb and/or honey. The other ingredients are added to the mixture and the combination is simmered to leach out the beneficial qualities thereof. The mixture is strained and placed in containers to cool and solidify. The salve has healing, pain relieving, anti-inflammatory, antiseptic, antibacterial properties and is water resistant and resistant to being easily washed or scraped off. The petroleum or castor bean jelly softens the skin to improve active ingredient interaction with the damaged skin.
The invention belongs to the field of medicine and particularly relates to a traditional Chinese medicine composition for treating lower limb numbness caused by phlegm-dampness accumulation in collaterals after an operation of lumbar intervertebral disc prolapse. The traditional Chinese medicine composition comprises, by weight, 4-8 parts of root of ardisia crispa (Thunb.) A.DC. [Bladhia crispa Thunb.], 4-8 parts of fruit of pandanus tectorius Soland., 4-8 parts of pericarp of common sterculia, 4-8 parts of root-bark of spinystem aralia, 4-8 parts of berchemia racemosa Sieb. et Zucc., 4-8 parts of herba alyxiae sinensis, 4-8 parts of phlegmariurus petiolatus, 4-8 parts of root tuber of gynura pseudo-china (L.) DC., 4-8 parts of vittaria modesta Hand.-Mazz.[V.nana Ching], 4-8 parts of Chinese alangium root and 4-8 parts of liquorice. The traditional Chinese medicine composition is capable of removing dampness, reducing phlegm, regulating qi and promoting blood circulation to remove meridian obstruction by combining the traditional Chinese medicines, and can relieve patient's numbness symptom effectively and recover patient's nerve shallow and deep feeling functions by focusing on etiology and pathogenesis of the lower limb numbness caused by phlegm-dampness accumulation in collaterals after the operation of the lumbar intervertebral disc prolapse, thereby being applicable to patients differentiated as lower limb numbness caused by phlegm-dampness accumulation in collaterals after the operation.
FIELD: chemistry.SUBSTANCE: invention relates to means of microbial growth suppression. An antimicrobial composition contains an acyl lactylate selected from the group consisting of sodium isostearoyl lactylate, sodium caproyl/lauroyl lactylate, sodium lauroyl lactylate and combinations thereof, a glycol selected from the group consisting of propylene glycol, 1,2-hexanediol, methylpropanediol and isopentyl and combinations thereof, and a carrier. The carrier contains water, wherein water makes up for more than 95% wt. of the composition. Optionally, the antimicrobial composition comprises one or more ingredients selected from the group consisting of a pH adjusting ingredient and a fragrance. The antimicrobial composition is designed for use in a method of microbial growth suppression in a product through application thereof to the product. The antimicrobial composition is also applied to a substrate resulting in antimicrobial towels.EFFECT: proposed antimicrobial composition provides effective removal of microbiological contamination on any surfaces, food and hygiene products, prevents recontamination and is safe for use in humans and animals.13 cl, 7 tbl, 23 ex
PROBLEM TO BE SOLVED: To obtain an osteo enhancer having osteo enchancing effect, capable of inhibiting and treating several diseases such as bone fracture, rheumatism, articular inflammation, lumbago, osteoporosis, etc., by containing deoxyribonucleic acid as an active ingredient. SOLUTION: This osteo enhancer uses deoxyribonucleic acid(DNA) obtained from soft roe, etc., of salmon, trout, cod, etc., as an active ingredient. The molecular weight of the DNA is preferably above 1000. The osteo enhancer using DNA as the active ingredient, can be formulated to afford an osteo enhancing foods, eatables, drinkables and feedstuff for animals. The content of the DNA is 0.1-10% in the case of medicines. The DNA is administered at a daily does as 0.5-1.5 g for adults as medicines.
INTRODUCTION: Infants exposed to enteropathogens through poor sanitation and hygiene can develop a subclinical disorder of the gut called environmental enteric dysfunction (EED), characterised by abnormal intestinal histology and permeability. EED can contribute to stunting through reduced digestion and absorption of nutrients, increased susceptibility to infections, increased systemic inflammation and inhibition of growth hormones. EED can be apparent by age 12 weeks, highlighting the need for early intervention. Modulating the early life gut microbiota using synbiotics may improve resistance against colonisation of the gut by enteropathogens, reduce EED and improve linear growth.
METHODS AND ANALYSIS: An individually randomised, two-arm, open-label, controlled trial will be conducted in Kaffrine District, Senegal. Infants will be recruited at birth and randomised to either receive a synbiotic containing two Bifidobacterium strains and one Lactobacillus strain, or no intervention, during the first 6 months of life. The impact of the intervention will be evaluated primarily by comparing length-for-age z-score at 12 months of age in infants in the intervention and control arms of the trial. Secondary outcome variables include biomarkers of intestinal inflammation, intestinal integrity and permeability, gut microbiota profiles, presence of enteropathogens, systemic inflammation, growth hormones, epigenetic status and episodes of illness during follow-up to age 24 months.
DISCUSSION: This trial will contribute to the evidence base on the use of a synbiotic to improve linear growth by preventing or ameliorating EED in a low-resource setting.
TRIAL REGISTRATION NUMBER: PACTR202102689928613.
Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
FIELD: chemistry. ^ SUBSTANCE: invention belongs to polymeric container for storage of prostaglandin F2 derivate aqueous preparation. Derivate has at least one fluor atom in its molecule. Polymeric container is made of propylene/ethylene copolymer in which propylene/ethylene ratio varies from 94.0/6.0 to 99.5/0.5. This container provides long time storage of prostaglandin F2 derivate liquid aqueous solution. ^ EFFECT: long time storable in aforementioned polymeric container product is offered. ^ 5 cl, 1 dwg, 1 ex
The data for study will be collected for the duration of 5 months, data will be collected at 1st, 4th, 8th, 12th and then at 16th week of follow up. It is a Randomized Control Trial. Patients will be selected by Consecutive Sampling from Ittefaq Hospital Trust, Lahore. All patients were right handed prior to stroke. Screening tools used will be Canadian Neurological Scale, the Mini-Mental State Examination (MMSE), the Bell Barrage test, and the ideomotor apraxia test (SpinnlerRognoni).Tests for assessment will be Fugl-Meyer test (FM) (of the upper limb), Frenchay Arm test (FAT), Box and Block test (BBT), Modified Ashworth Scale (AS) and Functional Independence Measure Motor items (FIMM). The SPSS version 21 will be used for analyzing data. The descriptive data will be expressed in Frequency and Percentages, while within the group differences will be measured by Mixed Model Anova.
The invention belongs to the field of stem cells and biotechnology, and relates to a novel application of adipose-derived mesenchymal stem cells. Firstly, the invention provides a method for constructing adipose-derived mesenchymal stem cells carrying miR-122. In addition, the invention also discloses an application of the adipose-derived mesenchymal stem cells carrying miR-122 in the preparation of liver cancer chemosensitization preparations. The adipose-derived mesenchymal stem cells (AMSC) carrying miR-122 are used for preparing a chemosensitization agent and are combined with clinically conventional chemotherapeutic drugs so as to be applied to the chemotherapy of a liver cancer tumor-bearing mice model, so that the sensitivity of heterotopic or in-situ tumor tissues to the chemotherapeutic drugs can be obviously improved, the chemotherapy effect is enhanced, and the progress of the liver cancer is blocked. The dosage of the chemotherapeutic drugs can be reduced, and the chemotherapy side reaction is alleviated. The invention provides a technical support for preparing a novel liver cancer chemotherapy targeting sensitizer and a new method for the system chemotherapy of the liver cancer.
The lymphatic system (or lymphatics) consists of lymphoid organs and lymphatic vessels. Despite the numerous previously published studies describing conditions related to perirenal and intrarenal lymphoid organs in the radiology literature, the radiologic findings of conditions related to intrarenal and perirenal lymphatic vessels have been scarcely reported. In the renal cortex, interlobular lymphatic capillaries do not have valves; therefore, lymph can travel along the primary route toward the hilum, as well as toward the capsular lymphatic plexus. These two lymphatic pathways can be opacified by contrast medium via pyelolymphatic backflow at CT urography, which reflects urinary contrast agent leakage into perirenal lymphatic vessels via forniceal rupture. Pyelolymphatic backflow toward the renal hilum should be distinguished from urinary leakage due to urinary injury. Delayed subcapsular contrast material retention via pyelolymphatic backflow, appearing as hyperattenuating subcapsular foci on CT images, mimics other subcapsular cystic diseases. In contrast to renal parapelvic cysts originating from the renal parenchyma, renal peripelvic cysts are known to be of lymphatic origin. Congenital renal lymphangiectasia is mainly seen in children and assessed and followed up at imaging. Several lymphatic conditions, including lymphatic leakage as an early complication and acquired renal lymphangiectasia as a late complication, are sometimes identified at imaging follow-up of kidney transplant. Lymphangiographic contrast material accumulation in the renal hilar lymphatic vessels is characteristic of chylo-urinary fistula. Chyluria appears as a fat-layering fluid-fluid level in the urinary bladder or upper urinary tract. Recognition of the anatomic pathway of tumor spread via lymphatic vessels at imaging is of clinical importance for accurate management at oncologic imaging. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material.
Disclosed are cellular compositions, grafts and pharmaceutical products made from bone marrow (BM) cells useful for a wide array of cell-based therapies for diseases and disorders of the nervous system. Transgenic cells in accord with the invention express therapeutic or reporter genes encoded in viral vectors. The cells are capable of extensive expansion in vitro and can generate neurons and glial cells both in culture and in vivo. Upon administration to a nervous system tissue or site in a host subject, the cells can migrate to appropriate target sites and can assimilate therein, differentiating into both neurons and astrocytes without evidence of fusion with endogenous cells of the host nervous tissue. The cells can express an array of therapeutic gene products suitable for treatment of nervous system disorders. Particularly preferred for neurodegenerative disease applications are transgenic BM-derived neurogenic cells expressing neurotrophic factors.
The invention discloses application of geraniin in preparing a medicament for treating burns and scalds. The geraniin is applied to preparing the medicine for treating burns and scalds. The Geraniin is Geraniin monomer or Geraniin salt or their combination. The geraniin can lead the expression peak to be advanced by up-regulating the protein and gene expression level of FGF-2/PDGF-BB/PDGFR-beta axis. Geraniin (8g/kg) can reduce inflammatory reaction of wound surface by inhibiting generation and release of inflammatory mediator; meanwhile, the expression peak of the protein and gene expression level of the FGF-2/PDGF-BB/PDGFR-beta axis is advanced by up-regulating the protein and gene expression level of the FGF-2/PDGF-BB/PDGFR-beta axis, so that the decrustation and hair growth time of a rat is shortened, and the healing rate of a wound surface is improved. The geraniin has obvious treatment effect on burns and scalds, and is even better than the curative effect of 1 percent silver sulfadiazine (10g/kg) of the first-line clinical medicine.
Identifying effective treatment(s) for sarcopenia and sarcopenic obesity is of paramount importance as the global population advances in age and obesity continues to be a worldwide concern. Evidence has shown that a ketogenic diet can be beneficial for the preservation of muscle quality and function in older adults, but long-term adherence is low due in part to the high-fat (≥80%), very low carbohydrate (<5%) composition of the diet. When provided in adequate amounts, exogenous ketone esters (KEs) can increase circulating ketones to concentrations that exceed those observed during prolonged fasting or starvation without significant alterations in the diet. Ketone esters first emerged in the mid-1990s and their use in preclinical and clinical research has escalated within the past 10-15 years. We present findings from a narrative review of the existing literature for a proposed hypothesis on the effects of exogenous ketones as a therapeutic for preservation of skeletal muscle and function within the context of sarcopenic obesity and future directions for exploration. Much of the reviewed literature herein examines the mechanisms of the ketone diester (R,S-1,3-butanediol diacetoacetate) on skeletal muscle mass, muscle protein synthesis, and epigenetic regulation in murine models. Additional studies are needed to further examine the key regulatory factors producing these effects in skeletal muscle, examine convergent and divergent effects among different ketone ester formulations, and establish optimal frequency and dosing regimens to translate these findings into humans.
Ovarian cancer (OvCa) is characterized by early metastasis and high mortality rates, underscoring the need for deeper understanding of these aspects. This study explores the role of glucose transporter 3 (GLUT3) driven by zinc finger E-box-binding homeobox 1 (ZEB1) in OvCa progression and metastasis. Specifically, this study explored whether ZEB1 promotes glycolysis and assessed the potential involvement of GLUT3 in this process in OvCa cells. Our findings revealed that ZEB1 and GLUT3 were excessively expressed and closely correlated in OvCa. Mechanistically, ZEB1 activates the transcription of GLUT3 by binding to its promoter region. Increased expression of GLUT3 driven by ZEB1 dramatically enhances glycolysis, and thus fuels Warburg Effect to promote OvCa progression and metastasis. Consistently, elevated ZEB1 and GLUT3 expression in clinical OvCa is correlated with poor prognosis, reinforcing the profound contribution of ZEB1-GLUT3 axis to OvCa. These results suggest that activation of GLUT3 expression by ZEB1 is crucial for the proliferation and metastasis of OvCa via fueling glycolysis, shedding new light on OvCa treatment.